FDA approves overdose drug Narcan as 1st over-the-counter opioid treatment
The Food and Drug Administration on Wednesday approved over-the-counter sales of Narcam, the leading version of the opioid overdose reversal drug naloxone. Narcan is the first opioid treatment to get approval for sale without a prescription, and advocates and the Biden administration hope wider distribution will cut the number of Americans dying from fentanyl, heroin, oxycodone, and other opioid overdoses. Almost two-thirds of the 107,000 U.S. overdose deaths recorded in 2021 were from the synthetic opioid fentanyl.
Addiction and overdose experts said the efficacy of selling Narcan over the counter will depend on how many stores decide to stock it, where and how they display it on shelves, whether insurance plans will cover it, and how much its manufacturer, Emergent BioSolutions, decides to charge for a two-dose nasal spray package. Currently, the two-dose package of Narcan reportedly sells for about $47.
The FDA is likely to approve a second OTC naloxone spray, RiVine, which the nonprofit Harm Reduction Therapeutics sells for about $18 a unit, The Washington Post reports, and generic versions would be even cheaper if approved.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
![https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg](https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516-320-80.jpg)
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The FDA said, after Emergent studied the issue, that Narcan requires no specialty training to administer. One dose typically revives people overdosing on opioids, though fentanyl overdoses can require several doses. Before administering Narcan, people should call 911 and request an ambulance. Emergent said Narcan should be available on store shelves by late summer.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Big Tech's answer for AI-driven job loss: universal basic income
In The Spotlight A new study reveals the strengths and limitations
By Joel Mathis, The Week US Published
-
'I will not be silent' on Gaza, says Kamala Harris
Speed Read In a meeting with Israeli Prime Minister Benjamin Netanyahu, Harris supported Israel's right to defend itself while expressing a desire to end Palestinian suffering
By Arion McNicoll, The Week UK Published
-
'How long can TikTok dominate as a social network?'
Instant Opinion Opinion, comment and editorials of the day
By Justin Klawans, The Week US Published
-
Mushroom edibles are tripping up users
the explainer The psychedelics can sometimes have questionable components
By Devika Rao, The Week US Published
-
Rapamycin: the popular drug for longevity among biohackers
Under the Radar Living longer may be getting easier
By Devika Rao, The Week US Published
-
Pharmaceutical companies are warning of a rise in knockoff drugs
Under the Radar The World Health Organization is also urging consumers to be cautious
By Justin Klawans, The Week US Published
-
FDA panel rejects ecstasy to treat PTSD
Speed Read It cited flawed study data and the potential for abuse
By Peter Weber, The Week US Published
-
The push to ban decaf coffee
Under the radar Going caffeine-free can be risky
By Devika Rao, The Week US Published
-
US overdose deaths fell in 2023, still topped 100k
Speed Read New CDC data shows drug overdose deaths dropped for the first time in five years
By Peter Weber, The Week US Published
-
What reclassifying cannabis could change
The Explainer The Biden administration's move to change marijuana from a Schedule I narcotic to Schedule III could reshape the pot landscape even if it doesn't mean full federal legalization
By Rafi Schwartz, The Week US Published
-
Texas dairy worker gets bird flu from infected cow
Speed Read The virus has been spreading among cattle in Texas, Kansas, Michigan and New Mexico
By Peter Weber, The Week US Published